Roche gets early appeal on Taq patents:
This article was originally published in Clinica
Executive Summary
Roche has persuaded a US appeal court to consider separately two of its PCR patents that were challenged in a federal district court decision in favour of Promega. According to Roche, Promega's actions directly infringed two US PCR patents, 4,638,195 and 4,683,202 and Promega's actions to induce others to use the native Taq enzyme for PCR procedures indirectly infringed the PCR patents. In December Promega won a decision against Roche concerning natural Taq which Promega claimed could have jeopardised Roche's entire PCR patent portfolio (see Clinica No 888, p 7).
You may also be interested in...
Post-Brexit UK Risks Being ‘Left Out In The Cold’ As EU Coordinates Action On Shortages
The UK is not alone in experiencing drug shortages, as data from across Europe show, but its departure from the EU makes it more difficult to respond to supply chain pressures, according to new research.
Dr Reddy’s Knocked Back On Rituximab In US
Dr Reddy’s has received a complete response letter from the US FDA, knocking back its proposed rituximab biosimilar rival to Rituxan.
Sandoz And Samsung Celebrate Stelara Rival’s EU Approval
Sandoz and Samsung Bioepis have received final European Commission approval for their partnered Pyzchiva biosimilar rival to Stelara. But with European competition on ustekinumab due to kick off in just a matter of months, further applicants are also waiting in the wings.